Informal social gatherings such as birthdays may be associated with an increased risk of household COVID-19 transmission in areas with high COVID-19 prevalence, according to a cross-sectional study conducted in the US.
A multidrug regimen containing inhaled amikacin with or without clofazimine improves outcomes in patients with pulmonary disease (PD) caused by Mycobacterium abscessus subspecies massiliense, according to a study. However, the regimen shows only moderate efficacy in treating infections with the abscessus subspecies.
The mRNA-1273 SARS-CoV-2 vaccine developed by Moderna demonstrates satisfactory safety profile in adolescents and produces an immune response comparable to that in young adults, according to the results of an interim analysis of an ongoing trial.
In the 96-week interim analysis of the phase III BRIGHTE study presented at IAS 2021, the gp120 attachment inhibitor fostemsavir showed favourable safety and tolerability, and yielded strong rates of virologic response in heavily treatment-experienced (HTE) adults infected with extensive multidrug-resistant (MDR) HIV-1.
The combined regimen of bedaquiline, pretomanid, and linezolid (BPaL) may help treat highly drug-resistant tuberculosis (TB), even with lower doses or shorter treatment duration of linezolid, according to results of the phase III ZeNix trial presented at IAS 2021.
Nearly 2 years into the pandemic, researchers worldwide scramble to find a cure for COVID-19 but are disappointed over and over, as trials churn out unsatisfactory results for various repurposed drugs examined. However, one or two agents have shown promising results in terms of patient survival.
Treatment with the single-tablet regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) leads to sustained viral suppression through 4 years with no treatment-emergent resistance in treatment-naïve people living with HIV (PWH), according to a long-term study presented at IAS 2021.
Sepsis continues to be a chief cause of health loss across the globe despite decreasing age-standardized incidence and mortality, according to a study presented at the Asia Pacific Intensive Care Symposium (APICS) 2021 virtual conference. Moreover, the disorder has particularly high health-related burden in Southeast Asia, South Asia, East Asia, Oceania, and sub-Saharan Africa.
The risk of contracting Trichomonas vaginalis (TV) infection seems to be higher in women using copper intrauterine devices (Cu-IUD) as a contraceptive, according to a study presented at the recently concluded 2021 International AIDS Society Conference on HIV Science (IAS 2021).
About four-fifths of heavily treated HIV patients with multidrug resistance have achieved viral suppression with the investigational long-acting subcutaneous lenacapavir (LEN) used in combination with an optimized antiretroviral (ART) regimen, according to the 26-week data from the ongoing phase II/III CAPELLA study.